Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03003728
Title 2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Arkansas
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.